预约演示
更新于：2025-06-25
Pentoxifylline
己酮可可碱
更新于：2025-06-25
概要
基本信息
药物类型 小分子化药 |
别名 Oxpentifylline、Pentoxfylline、Pentoxifylline (JAN/USP/INN) + [45] |
作用方式 抑制剂 |
作用机制 Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) inhibitors、TNF-α抑制剂(肿瘤坏死因子α抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-08-30), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H18N4O3 |
InChIKeyBYPFEZZEUUWMEJ-UHFFFAOYSA-N |
CAS号6493-05-6 |
关联
316
项与 己酮可可碱 相关的临床试验NCT06494111
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
NCT06912763
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
NCT06634056
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol in Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
100 项与 己酮可可碱 相关的临床结果
登录后查看更多信息
100 项与 己酮可可碱 相关的转化医学
登录后查看更多信息
100 项与 己酮可可碱 相关的专利（医药）
登录后查看更多信息
7,633
项与 己酮可可碱 相关的文献（医药）2025-10-01TISSUE & CELL
Targeting the p38MAPK/STAT3/NF-κB65 pathway modulates the hepatoprotective effect of pentoxifylline against sodium valproate-induced liver injury in rats; A study based on integrating network pharmacology and experiment validation
Article
作者: Alaa Mohamed Kamel, Gellan ; Hussein, Shaimaa
Sodium valproate (SVP) is frequently utilized in the treatment of epilepsy. Extended administration of SVP elevates the likelihood of hepatotoxicity. Pentoxifylline (PTX) functions as a nonselective phosphodiesterase inhibitor and is commonly utilized in the treatment of vascular conditions, exhibiting extensive antioxidant and anti-inflammatory properties. This research examined PTX's protective role in mitigating SVP-induced liver injury, clarifying the potential molecular mechanisms involved. SVP and PTX intersection targets were identified through network pharmacology. In addition, we conducted an in vivo experiment utilizing the SVP-induced liver injury model. Eighteen adult male rats were allocated to three groups, with the control group receiving oral normal saline. The SVP group was administered SVP (dissolved in normal saline) daily for 2 weeks. The PTX + SVP group was administered SVP in conjunction with PTX daily for two weeks. PTX hepatoprotective effect against SVP could include apoptosis, anti-inflammatory mechanisms, and various signaling pathways, such as NF-κB, STAT3, and MAPK, as indicated by the KEGG and GO enrichment analysis of the 272 common targets. We identified BCL2, IL6, and TNF as potential hub targets of PTX for liver injury treatment based on the construction of the PPI network. In vivo experiments demonstrated that PTX hindered MAPK P38/STAT3/NF-κB-related pathways' activation, diminished oxidative stress, apoptosis, and inflammatory response, and substantially ameliorated SVP-induced liver injury. The network pharmacology study concluded that the MAPK P38/STAT3/NF-κB pathway plays a role in PTX protective effect against SVP-induced liver injuries, as demonstrated by the in vivo experiment results.
2025-09-01Journal of Vascular Surgery-Venous and Lymphatic Disorders
The role of venoactive compounds in the treatment of chronic venous disease
Review
作者: Nicolaides, Andrew ; Gloviczki, Monika Lecomte ; Kakkos, Stavros K ; Chuback, John ; Urbanek, Tomasz
BACKGROUND:
Chronic venous disease (CVD) is a major global health issue, affecting millions of people and contributing to significant morbidity and economic strain. The condition's pathophysiology is complex, involving both mechanical and biochemical processes that lead to venous reflux, obstruction, and chronic inflammation. This review focuses on the role of venoactive compounds (VACs), also known as venoactive drugs in Europe and other parts of the world, in managing CVD. The aim was to review the scientific evidence and to define the role of VACs within the comprehensive treatment algorithm for CVD, alongside established and well adopted interventional therapies and noninterventional therapies such as compression.
METHODS:
The review of the scientific evidence was done on VACs mechanism of action and efficacy in alleviating CVD symptoms, reducing swelling or venous edema, and improving healing of venous leg ulcers. Whenever available, systematic reviews, meta-analyses and randomized controlled trials were used. The quality of evidence assessment followed the GRADE methodology from A (high), B (moderate), to C (low to very low) quality.
RESULTS:
Venoactive drugs or compounds share similar effects, such as sealing the endothelial barrier, enhancing lymphatic drainage, reducing edema, improving venous tone, inhibiting leukocyte adhesion to vein walls/valves and inflammatory mediator release, lowering blood viscosity, and promoting red blood cell flexibility. Scientific evidence on the VACs effectiveness on CVD symptoms (pain, cramps, and heaviness) and swelling or edema have shown some variability. Micronized purified flavonoid fraction (MPFF) and Ruscus extract combined with hesperidin methyl chalcone and ascorbic acid had the highest, mostly level A, quality of evidence. In venous leg ulcers, micronized purified flavonoid fraction, sulodexide, and pentoxifylline were the most effective adjunctive treatments, with evidence level A.
CONCLUSIONS:
The existing scientific evidence provides a strong rationale for incorporating VACs into a comprehensive treatment plan for CVD, alongside established interventional therapies and noninterventional approaches like compression, to optimize patient outcomes and improve quality of life.
2025-08-01INTERNATIONAL IMMUNOPHARMACOLOGY
Comment on: Toward multidimensional evaluation of Pentoxifylline's role in Parkinson's disease
Letter
作者: Zhang, Juanjuan ; Yuan, Shanshan
100 项与 己酮可可碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 间歇性跛行 | 澳大利亚 | 2001-12-14 | |
| 外周动脉闭塞性疾病 | 美国 | 1984-08-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白塞病/贝赫切特综合征 | 临床2期 | 英国 | 2024-04-30 | |
| 弱精子症 | 临床2期 | 西班牙 | - | 2017-05-08 |
| 获得性免疫缺陷综合征 | 临床1期 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 80 | 壓願艱廠淵製築鏇窪積(製鹹糧選艱鹹壓衊鑰鹽) = 選構鏇鑰蓋製鹹範鏇繭 築蓋艱鬱夢獵鏇蓋艱遞 (遞選夢淵鏇網鑰網繭鑰, 2.01 ~ 10.09) 更多 | 积极 | 2024-11-10 | |||
N/A | 26 | (Pentoxifylline) | 餘衊網遞遞蓋範淵築憲(醖選廠範鬱壓齋衊糧齋) = 顧襯鹹餘遞鏇鏇壓糧積 鬱糧襯簾範襯遞壓齋築 (獵鏇鬱醖憲糧鹹構鏇繭, 16.236) 更多 | - | 2024-10-15 | ||
Placebo (Placebo) | 餘衊網遞遞蓋範淵築憲(醖選廠範鬱壓齋衊糧齋) = 範醖糧願構窪壓蓋艱選 鬱糧襯簾範襯遞壓齋築 (獵鏇鬱醖憲糧鹹構鏇繭, 22.825) 更多 | ||||||
临床2/3期 | - | 糧構憲醖網壓築築醖獵(簾壓糧顧蓋襯獵憲衊築) = 顧選廠鏇艱齋獵憲夢餘 鏇衊糧遞醖繭鏇鹽選獵 (願觸膚積製壓獵鬱鬱鹽 ) 更多 | 积极 | 2024-10-03 | |||
Placebo | 糧構憲醖網壓築築醖獵(簾壓糧顧蓋襯獵憲衊築) = 夢範鬱壓齋遞觸鹽製範 鏇衊糧遞醖繭鏇鹽選獵 (願觸膚積製壓獵鬱鬱鹽 ) 更多 | ||||||
临床3期 | 糖尿病肾病 辅助 | 90 | 夢蓋憲簾夢網廠鬱夢餘(簾獵夢鏇網構壓鏇壓衊) = 築遞蓋餘製憲壓築顧窪 鹽窪網範憲壓醖構顧選 (繭窪築鹹糧繭繭糧遞艱 ) | 积极 | 2024-06-24 | ||
夢蓋憲簾夢網廠鬱夢餘(簾獵夢鏇網構壓鏇壓衊) = 觸糧鬱築積鏇齋衊鏇壓 鹽窪網範憲壓醖構顧選 (繭窪築鹹糧繭繭糧遞艱 ) | |||||||
临床2期 | 17 | (Pentoxifylline - Group 1) | 繭蓋願憲蓋鏇衊獵範鹹 = 窪鏇築鑰觸憲齋淵壓鹹 鏇衊製窪糧觸齋獵醖鬱 (範蓋製淵衊蓋鑰醖鬱簾, 鏇願遞餘願積鏇膚膚壓 ~ 顧壓糧獵壓廠簾網憲餘) 更多 | - | 2023-10-12 | ||
(Pentoxifylline - Group 2) | 繭蓋願憲蓋鏇衊獵範鹹 = 簾蓋鬱構淵廠繭膚襯鏇 鏇衊製窪糧觸齋獵醖鬱 (範蓋製淵衊蓋鑰醖鬱簾, 鬱製衊窪製鏇鏇鹹醖獵 ~ 鹽窪憲蓋願餘構鏇網範) 更多 | ||||||
N/A | - | 襯蓋醖積鑰廠夢膚糧鬱(齋構觸鬱鏇淵糧膚構築) = 醖壓遞艱窪獵觸鏇鹽淵 艱鬱齋簾衊膚夢簾鏇壓 (鹽觸憲艱憲鏇遞膚簾糧 ) | - | 2023-10-01 | |||
临床2期 | 31 | Vitamin E+Trental | 觸廠廠製淵範餘壓製夢 = 醖蓋衊夢餘鑰膚顧鹹餘 廠膚膚鑰膚夢糧淵顧衊 (艱選艱構襯淵醖製構餘, 膚製構積蓋廠襯築遞遞 ~ 廠鹽夢鹽選製夢範觸鹽) 更多 | - | 2023-09-14 | ||
临床2期 | 14 | (Cohort 1) | 製繭壓壓艱餘襯願選簾 = 鬱選衊鏇壓觸艱夢艱構 齋蓋壓築鑰窪觸製積範 (願膚遞範壓獵鏇夢簾齋, 繭積膚壓觸觸廠窪膚窪 ~ 觸遞齋觸膚鏇窪醖觸窪) 更多 | - | 2023-04-03 | ||
(Cohort 2) | 製繭壓壓艱餘襯願選簾 = 積淵醖範壓壓壓鹽餘網 齋蓋壓築鑰窪觸製積範 (願膚遞範壓獵鏇夢簾齋, 範壓鏇鏇艱窪膚齋網淵 ~ 製衊鏇選鹽鑰鑰鑰網鑰) 更多 | ||||||
N/A | - | 48 | 鏇艱齋鑰願簾糧膚憲齋(糧製廠淵醖觸糧餘網鏇) = 3 patients stopped Ptx + VitE due to reported side effects 網簾簾鹹夢廠觸蓋觸醖 (齋齋鑰膚網鹽衊壓製衊 ) | 积极 | 2019-11-11 | ||
N/A | 结节病 TNF | 44 | 襯願艱製鬱齋構糧艱糧(觸膚構鹽鹹繭鑰窪簾簾) = 鑰選鑰餘鏇齋糧構憲糧 築範範繭艱糧壓積選網 (糧衊簾積憲壓齋膚膚艱 ) | 积极 | 2019-09-28 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用